Longer Progression-Free Survival for Durvalumab in NSCLC
Longer median progression-free survival from randomization, higher response rate with durvalumab
‘Modest at Best’ Discriminatory Ability for CBC Test in Infants
Findings among febrile infants (≤60 days) with invasive bacterial infections
Median Cost of Cancer Drug Development $648.0 Million
Total revenue from sales of 10 drugs was $67.0 billion, with total R&D spending of $7.2 billion
AAO-HNS: Improvement in OSA With Cranial Nerve Stimulation
Decrease in apnea-hypopnea index, and improvement in oxygen saturation, sleepiness, quality of life
Center Surgical Volume Linked to LVAD Patient Outcomes
Worse survival at centers performing ≤10 left ventricular assist device implants/year
Airway Mucin Concentrations May Help Predict Chronic Bronchitis
Mean total mucin concentrations up in smokers with severe COPD, those with respiratory exacerbations
Zoonotic Chlamydia caviae Tied to Community-Acquired Pneumonia
Three cases of community-acquired pneumonia reported after exposure to ill guinea pigs
Statins Tied to Reduced Mortality Risk in COPD
Statin exposure associated with lower all-cause, pulmonary mortality
Tiotropium Effective in Mild to Moderate COPD
Daily inhaled dose tied to improvements in FEV1 compared to placebo
Reduced Asthma Exacerbations Seen With Tezepelumab
Reduction seen with three dose levels of tezepelumab regardless of blood eosinophil counts
